Tratamiento de la anemia hiporregenerativa tardía de la enfermedad hemolítica del recién nacido con eritropoyetina recombinante

introduction. the aim of the study is to report results of erythropoietin treatment for late hyporegenerative anemia in the hemolytic disease of the newborn (hdn). reports previously published concern only a few cases, with controversial results. methods. case series report concerning 50 neonates with hdn due to rh, abo or kpa antigens, aged more than 7 days. erythropoietin treatment started when hematocrit dropped to levels requiring transfusion, with an inappropriate reticulocyte response (reticulocyte production index <1). results. at start of treatment mean age was 24.3 ± 12.0 days (range 8-65 days), hematocrit 24.1 ± 2.8% (range 18-30%), and reticulocyte production index 0.34 ± 0.25 (range 0.05-0.98). hematocrit and reticulocyte production index showed significant increases after 7 and 14 days of treatment (p <0.001). no difference was observed either between infants with rh-hdn and abo-hdn or between rh-hdn patients with or without intrauterine transfusions. seven infants (14%) required one packed rbc transfusion during erythropoietin therapy, 2 of them within 72 hours from starting treatment. the percentage of transfused infants showed no difference either between abo-hdn and rh-hdn or between rh-hdn with and without intrauterine transfusions. moderate, short-lasting neutropenia, not associated to infections, was observed in 11 patients. no other adverse effect was observed. conclusions. the administration of erythropoietin appears to be a safe and useful therapy. its efficacy should be confirmed by randomized studies.